Gyre Therapeutics, Inc. Other Income and Expense
Gyre Therapeutics, Inc. (GYRE) reported Other Income and Expense of $61.00 thousand for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-07-31.
Discontinued › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2015-07-31
- Gyre Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2015-06-30 was $61.00K, a 58.78% decline year-over-year.
- Gyre Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2015-03-31 was $92.00K, a 45.56% decline year-over-year.
- Gyre Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2014-12-31 was $119.00K.
- Gyre Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2014-09-30 was $139.00K, a 43.03% decline year-over-year.
- Gyre Therapeutics, Inc. nonoperating income (expense) for fiscal 2014 was $575.00K, a 11.00% increase from fiscal 2013.
- Gyre Therapeutics, Inc. nonoperating income (expense) for fiscal 2013 was $518.00K, a 50.14% decline from fiscal 2012.
- Gyre Therapeutics, Inc. nonoperating income (expense) for fiscal 2012 was $1.04M, a 14.56% decline from fiscal 2011.
- Gyre Therapeutics, Inc. nonoperating income (expense) for fiscal 2011 was $1.22M, a 7.18% decline from fiscal 2010.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2015-06-30 | $61.00K 10-Q · filed 2015-07-31 | $153.00K 10-Q · filed 2015-07-31 | $272.00K derived: sum of 3 quarters · filed 2015-07-31 | $411.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2015-03-31 | $92.00K 10-Q · filed 2015-05-07 | $211.00K derived: sum of 2 quarters · filed 2015-05-07 | $350.00K derived: sum of 3 quarters · filed 2015-05-07 | $498.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $258.00K derived: sum of 2 quarters · filed 2015-03-16 | $406.00K derived: sum of 3 quarters · filed 2015-07-31 | $575.00K 10-K · filed 2015-03-16 |
| 2014-09-30 | $139.00K 10-Q · filed 2014-11-06 | $287.00K derived: sum of 2 quarters · filed 2015-07-31 | $456.00K 10-Q · filed 2014-11-06 | $405.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-06-30 | $148.00K 10-Q · filed 2015-07-31 | $317.00K 10-Q · filed 2015-07-31 | $266.00K derived: sum of 3 quarters · filed 2015-07-31 | $510.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-03-31 | $169.00K 10-Q · filed 2015-05-07 | $118.00K derived: sum of 2 quarters · filed 2015-05-07 | $362.00K derived: sum of 3 quarters · filed 2015-05-07 | $479.00K derived: sum of 4 quarters · filed 2015-05-07 |
| 2013-12-31 | -$51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $193.00K derived: sum of 2 quarters · filed 2015-03-16 | $310.00K derived: sum of 3 quarters · filed 2015-03-16 | $518.00K 10-K · filed 2015-03-16 |
| 2013-09-30 | $244.00K 10-Q · filed 2014-11-06 | $361.00K derived: sum of 2 quarters · filed 2014-11-06 | $569.00K 10-Q · filed 2014-11-06 | $858.00K derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | $117.00K 10-Q · filed 2014-08-07 | $325.00K 10-Q · filed 2014-08-07 | $614.00K derived: sum of 3 quarters · filed 2015-03-16 | $833.00K derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | $208.00K 10-Q · filed 2014-05-08 | $497.00K derived: sum of 2 quarters · filed 2015-03-16 | $716.00K derived: sum of 3 quarters · filed 2015-03-16 | $974.00K derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | $289.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $508.00K derived: sum of 2 quarters · filed 2015-03-16 | $766.00K derived: sum of 3 quarters · filed 2015-03-16 | $1.04M 10-K · filed 2015-03-16 |
| 2012-09-30 | $219.00K 10-Q · filed 2013-11-06 | $477.00K derived: sum of 2 quarters · filed 2013-11-06 | $750.00K 10-Q · filed 2013-11-06 | $1.09M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-06-30 | $258.00K 10-Q · filed 2013-08-07 | $531.00K 10-Q · filed 2013-08-07 | $871.00K derived: sum of 3 quarters · filed 2014-03-14 | $1.15M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-03-31 | $273.00K 10-Q · filed 2013-05-08 | $613.00K derived: sum of 2 quarters · filed 2014-03-14 | $890.00K derived: sum of 3 quarters · filed 2014-03-14 | $1.20M derived: sum of 4 quarters · filed 2014-03-14 |
| 2011-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $617.00K derived: sum of 2 quarters · filed 2014-03-14 | $931.00K derived: sum of 3 quarters · filed 2014-03-14 | $1.22M 10-K · filed 2014-03-14 |
| 2011-09-30 | $277.00K 10-Q · filed 2012-11-08 | $591.00K derived: sum of 2 quarters · filed 2012-11-08 | $876.00K 10-Q · filed 2012-11-08 | $1.20M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-06-30 | $314.00K 10-Q · filed 2012-08-09 | $599.00K 10-Q · filed 2012-08-09 | $923.00K derived: sum of 3 quarters · filed 2013-03-15 | $1.25M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-03-31 | $285.00K 10-Q · filed 2012-05-09 | $609.00K derived: sum of 2 quarters · filed 2013-03-15 | $935.00K derived: sum of 3 quarters · filed 2013-03-15 | $1.26M derived: sum of 4 quarters · filed 2013-03-15 |
| 2010-12-31 | $324.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $650.00K derived: sum of 2 quarters · filed 2013-03-15 | $978.00K derived: sum of 3 quarters · filed 2013-03-15 | $1.31M 10-K · filed 2013-03-15 |
| 2010-09-30 | $326.00K 10-Q · filed 2011-11-03 | $654.00K derived: sum of 2 quarters · filed 2011-11-03 | $986.00K 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $328.00K 10-Q · filed 2011-08-09 | $660.00K 10-Q · filed 2011-08-09 | ||
| 2009-12-31 | $833.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |